pharmaphorum

JANUARY 6, 2023

The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the mRNA technologies that underpinned COVID-19 vaccines. The post UK partners with BioNTech on clinical trials of mRNA cancer therapies appeared first on.

Clinical Trials 112

Clinical Trials Clinical Trials Trials Vaccination 112

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology. Antibodies cover the pathogen of the virus and neutralise it.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

XTalks

AUGUST 27, 2020

With vaccine trials for COVID-19 ramping up and entering late stages, Johnson & Johnson has announced plans for what will be the largest Phase III trial so far for a vaccine against the novel coronavirus. This is double the enrollment that vaccine makers Moderna and Pfizer have planned for their Phase III trials.

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

XTalks

OCTOBER 26, 2023

The best way to prevent the flu is by getting vaccinated every year. The CDC and the World Health Organization (WHO) recommend annual flu vaccination for most people, especially those at high risk of serious complications, like pregnant women, elderly individuals, children and people with certain chronic health conditions.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

The Pharma Data

DECEMBER 2, 2020

Pontarollo’s extensive experience both as a microbiologist and biotech executive strengthens our team and gives EYAM significant momentum as we prepare to enter animal trials.” ” Prior to joining EYAM, Dr. Pontarollo spent 15 years at Genome Prairie serving both as Chief Scientific Officer and later as President and CEO.

Vaccination 52

Vaccination Vaccine Genome Genomics 52

Drug Discovery World

NOVEMBER 30, 2022

The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial. . This process requires the sequence of the viral protein, which can be determined from its genome and is then coupled with an optimised ‘clamp’ sequence. The University of Queensland. .

Vaccination 52

Vaccination Vaccine Immune Response Engineer 52

The Pharma Data

JANUARY 26, 2021

offered its genomics expertise to identify emerging variants of the SARS-CoV-2 virus to countries that lack the resources to make such identifications. has carried out more than half of all SARS-CoV-2 genome sequences submitted to the global database. On Tuesday, the U.K. The offer came as part of the U.K.’s South Africa and Brazil.

Genome 52

Genome Genomics Vaccination Vaccine 52

STAT News

NOVEMBER 3, 2022

Why don’t we run better clinical trials? Our colleague Matthew Herper joins us to discuss his thoughtful, personal story on how the biotech revolution that brought us genome editing, Covid-19 vaccines, and lifesaving medicines could run aground if humanity can’t get out of its own way.

Genome 98

Genome Genomics Clinical Trials Clinical Trials 98

Pharmaceutical Technology

JANUARY 20, 2023

In 2020, Moderna made a net loss of $747 million while its investigational mRNA vaccines were under development. However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. billion in Covid-19 vaccine sales.

Manufacturing 246

Manufacturing Vaccination Vaccine Gene Therapy 246

Pfizer

NOVEMBER 2, 2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Wed, 11/02/2022 - 15:44. Thursday, November 03, 2022 - 06:45am. Ugur Sahin, M.D.,

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

Pharmaceutical Technology

JUNE 20, 2023

The proposed institute will focus on vaccine research, public health research, therapeutics, genomics, diagnostics, clinical trials and data. It will be connected across multiple levels to the University of Melbourne’s Doherty Institute.

Biobanking 130

Biobanking Genome Genomics Clinical Trials 130

Drug Discovery World

JANUARY 9, 2023

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines. . The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. .

Research 52

Research Vaccination Vaccine Trials 52

Drug Discovery World

JULY 22, 2022

Covid-19 vaccines remain effective six months after second dose . Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.? . US launches clinical trial for pandemic preparation . News round-up by DDW’s Reece Armstrong for 18 – 22 July.

DNA 52

DNA Drugs Clinical Trials Clinical Trials 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. It is now following up with data from a small group of older adults, and they look positive. Targeted drug combo attacks breast cancer brain metastases in mice.

Vaccination 53

Vaccination Vaccine Research Trials 53

pharmaphorum

FEBRUARY 10, 2022

CVS Health has said it will beef up its clinical trials operations, improving its ability to recruit patients from a broad demographic spectrum, via an agreement with digital health company Medable. Pharmaceutical industry organisation PhRMA says that most delays to trials occur in the start-up phase.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Pharmacy 52

The Pharma Data

DECEMBER 14, 2020

ICU nurse Sandra Lindsay, with Long Island Jewish Medical Center in Queens, New York, received the Pfizer-BioNTech COVID-19 vaccine. Food and Drug Administration (FDA) ’ s Vaccines and Related Biological Products Advisory Committee on Thursday, December 17. Both vaccines have demonstrated about 94-95% efficacy in clinical trials.

Vaccination 52

Vaccination Vaccine Allergies Genome 52

pharmaphorum

JANUARY 5, 2023

and OriCiro Genomics K.K. The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio. Biotech Moderna, Inc.

Gene Sequencing 97

Gene Sequencing DNA Vaccination Vaccine 97

The Pharma Data

DECEMBER 28, 2020

Testing Therapies, Antivirals and Vaccines. The Nanovaccine Institute at Iowa State University (ISU) is using nanotechnology to develop a vaccine will be able to be administered without needles and in one dose. Health Canada granted authorization to the Moderna COVID-19 vaccine on December 23.

Genome 52

Genome Genomics Vaccination Vaccine 52

pharmaphorum

DECEMBER 20, 2022

Genomic profiling has made it possible to diagnose and treat patients with far greater precision. Often, the initial focus is on participating in the data revolution by expanding genomic sequencing capacity, implementing electronic health records (EHRs), and so on.

Genome 106

Genome Genomics Trials Doctors 106

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Antibody 52

Antibody Vaccination Vaccine Trials 52

The Pharma Data

JANUARY 11, 2021

health officials raced to ramp up the delivery of COVID-19 vaccines across the country as both coronavirus case counts and death tallies continued to hit record highs. “We really need to get this vaccine out more quickly, because this is really our only tool,” Dr. Scott Gottlieb, former commissioner of the U.S. .

Vaccination 52

Vaccination Vaccine Nurses Genome 52

XTalks

NOVEMBER 30, 2023

The safety and efficacy of Cabenuva were established through two randomized, open-label, controlled clinical trials involving 1,182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) before initiating Cabenuva treatment. The Phase I trial for HB-500 is scheduled to start in the first half of 2024.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

DECEMBER 10, 2020

–( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. 11, 2020 02:48 UTC. CULVER CITY, Calif.–(

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

XTalks

DECEMBER 13, 2023

Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. vaccine, mRNA-1273.815.

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

DECEMBER 24, 2020

From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. For example, investment in mRNA vaccines and viral vectors came well before January, many years before it.

Life Science 111

Life Science Vaccination Vaccine Gene 111

The Pharma Data

MARCH 3, 2021

(Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today provided an update on the VIR-7831 (GSK4182136) arm of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial.

Trials 52

Trials Antibody Vaccination Vaccine 52

XTalks

DECEMBER 17, 2021

The year continued to be dominated by COVID-19, and the second year of the pandemic was all about vaccines. And while over 8 billion doses of vaccines have been administered worldwide, billions more are still needed. And while over 8 billion doses of vaccines have been administered worldwide, billions more are still needed.

Life Science 98

Life Science Vaccination Vaccine Trials 98

Drug Discovery World

JULY 10, 2023

Its convergence with genomics makes sense and we have now multiple examples of AI being used to inform prescribing, diagnostics and drug discovery/ development. The team utilised genomic data from a database consisting of over 11,000 patients and which represented 33 types of human cancers. Disappointing, but work is continuing.

Gene Therapy 52

Gene Therapy Gene Scientist Gene Editing 52

Delveinsight

DECEMBER 15, 2020

ASC42 is an oral fatty acid synthase (FASN) inhibitor that has managed to significantly reduce the liver fat in Phase II clinical trial (FASCINATE-1). Pfizer, BioNTech COVID-19 Vaccine rolls out in a watershed moment. The vaccine is the first-ever mRNA vaccine to get to the EUA and is developed in record-time low.

Vaccination 54

Vaccination Vaccine Gene Therapy Gene 54

Drug Discovery World

MARCH 13, 2024

In 2019 he was part of a research team which discovered humanised antibody, PRL3-zumab, was effective at shrinking PRL3 over-expressing tumours, and which has since been approved for Phase II clinical trials in Singapore, the US and China. There has also been significant investment in infrastructure in the country.

Life Science 69

Life Science Genome Genomics Research 69

Drug Discovery World

JANUARY 21, 2024

As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay. As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay.

Protein 52

Protein Vaccination Vaccine Development 52

The Pharma Data

DECEMBER 30, 2020

Elsewhere across the globe: Arcturus Therapeutics – San Diego-based Arcturus Therapeutics received approval from the Singapore Health Sciences Authority to proceed with a Phase II clinical study of its vaccine candidate ARCT-021 against COVID-19. Belarus was also the first foreign country to begin clinical trials of Sputnik V.

Genome 52

Genome Genomics Immune Response Vaccination 52

Drug Discovery World

DECEMBER 12, 2022

In Nature 3 , we learnt about the CRISPR cancer trial success leading the way to personalised treatments. According to the publication, “A small clinical trial has shown that researchers can use CRISPR gene editing to alter immune cells so that they will recognise mutated proteins specific to a person’s tumours. Analysis .

Drugs 52

Drugs Gene Editing Genome Genomics 52

The Pharma Data

JANUARY 11, 2021

In clinical trials, it could detect COVID-19 with 90%+ accuracy in about two minutes. . Testing Therapies, Antivirals and Vaccines. By the end of January, Johnson & Johnson is expected to deliver preliminary trial results for its one-dose COVID-19 vaccine candidate. . Other Industry News.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

XTalks

DECEMBER 1, 2021

To ensure the new tests can identify Omicron based on its mutations, the companies assessed their tests against sequences in public databases of genomic data, such as GISAID and GenBank. Cue is also currently working with Google Cloud and genomics company Helix to study variants and share mutation sequencing data.

Gene 105

Gene Genome Genomics Genetics 105

Drug Discovery World

DECEMBER 16, 2022

An immunotherapy that uses a new targeted approach to kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials. . mRNA cancer vaccine meets primary efficacy endpoint . Experimental immunotherapy has over 70% response rate . New dermatitis treatment shows promising long-term results .

Drugs 52

Drugs Vaccination Vaccine Genetics 52

The Pharma Data

AUGUST 16, 2021

The antiviral agent incorporates RNA-like building blocks into the RNA genome of the virus. Molnupiravir is currently being tested in clinical trials. At full stretch, researchers are developing various vaccines and drugs – with different degrees of success. ” Mutations in the genome stop the virus. .”

RNA 52

RNA Drugs Genome Genomics 52